Market Capitalization (Millions $) |
113 |
Shares
Outstanding (Millions) |
39 |
Employees |
- |
Revenues (TTM) (Millions $) |
1 |
Net Income (TTM) (Millions $) |
-36 |
Cash Flow (TTM) (Millions $) |
-7 |
Capital Exp. (TTM) (Millions $) |
0 |
Beyondspring Inc
Beyondspring Inc is a clinical-stage pharmaceutical company that focuses on the development of innovative cancer therapies. The company is involved in discovering and developing novel immuno-oncology drugs to improve the outcomes of cancer patients. Beyondspring's drug candidates are designed to target specific mechanisms within the immune system to enhance anti-cancer response and reduce the relapse rate. Their flagship product, Plinabulin, has shown promising results in clinical trials for the treatment of various types of cancers, including non-small cell lung cancer and triple-negative breast cancer. Beyondspring Inc is dedicated to bringing new treatment options to patients and improving cancer care worldwide.
Company Address: 28 Liberty Street, 39th Floor New York 10005 NY
Company Phone Number: 305-6387 Stock Exchange / Ticker: NASDAQ BYSI
BYSI is expected to report next financial results on April 17, 2024. |
|
|